Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.

NCT01591655 is registered in ClinicalTrials.gov with Bausch & Lomb Incorporated as lead sponsor.

NCT NCT01591655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01591655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.
Lead sponsor
Bausch & Lomb Incorporated
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2012
Completion date
October 31, 2013
Enrollment
360 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cataract, inflammation, surgery